Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam

Autor:	Natalia de la Calle-Pedrosa, Alberto Delgado-Iribarren, Ángeles Gabán-Díez, Ignacio Temprano-Gómez, A. Hernández-Tejedor, Carmen Débora Merino-Vega, Alejandro Algora-Weber, Alfredo Martín-Vivas, Rafael Ruiz de Luna-González, Ana Isabel González-Jiménez
Rok vydání:	2016
Předmět:	Male 0301 basic medicine Microbiology (medical) Tazobactam medicine.drug_class 030106 microbiology Antibiotics Penicillanic Acid Bacteremia Microbial Sensitivity Tests medicine.disease_cause Microbiology 03 medical and health sciences 0302 clinical medicine Drug Resistance Multiple Bacterial polycyclic compounds medicine Humans Pseudomonas Infections 030212 general & internal medicine Pseudomonas aeruginosa business.industry CEFTOLOZANE/TAZOBACTAM Off-Label Use General Medicine Middle Aged biochemical phenomena metabolism and nutrition bacterial infections and mycoses medicine.disease Anti-Bacterial Agents Cephalosporins Infectious Diseases Amikacin Colistin bacteria Ceftolozane business medicine.drug
Zdroj:	Infection. 45:115-117
ISSN:	1439-0973 0300-8126
DOI:	10.1007/s15010-016-0944-5
Popis:	Ceftolozane/tazobactam is a novel antibiotic approved for the treatment of complicated intra-abdominal and complicated urinary tract infections. We describe the use of off-label ceftolozane/tazobactam in the management of a multidrug-resistant Pseudomonas aeruginosa bacteremia that was already being treated with colistin and amikacin, the only active antibiotics according to the antibiogram.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7164ac82d84948715500e368987dc8e4 https://doi.org/10.1007/s15010-016-0944-5 Zobrazit plný text záznamu Full text from SpringerLink